Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
This study aimed to evaluate well-documented diagnostic antigens, named B13, 1F8 and JL7 recombinant proteins, as potential markers of seroconversion in treated chagasic patients. Prospective study, involving 203 patients treated with benznidazole, was conducted from endemic areas of northern Argent...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Instituto Oswaldo Cruz, Ministério da Saúde
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909034/ |
| id |
pubmed-4909034 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-49090342016-06-16 Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina Niborski, Leticia L Grippo, Vanina Lafón, Sonia O Levitus, Gabriela García-Bournissen, Facundo Ramirez, Juan C Burgos, Juan M Bisio, Margarita Juiz, Natalia A Ayala, Vilma Coppede, María Herrera, Verónica López, Crescencia Contreras, Ana Gómez, Karina A Elean, Juan C Mujica, Hugo D Schijman, Alejandro G Levin, Mariano J Longhi, Silvia A Articles This study aimed to evaluate well-documented diagnostic antigens, named B13, 1F8 and JL7 recombinant proteins, as potential markers of seroconversion in treated chagasic patients. Prospective study, involving 203 patients treated with benznidazole, was conducted from endemic areas of northern Argentina. Follow-up was possible in 107 out of them and blood samples were taken for serology and PCR assays before and 2, 3, 6, 12, 24 and 36 months after treatment initiation. Reactivity against Trypanosoma cruzi lysate and recombinant antigens was measured by ELISA. The rate of decrease of antibody titers showed nonlinear kinetics with an abrupt drop within the first three months after initiation of treatment for all studied antigens, followed by a plateau displaying a low decay until the end of follow-up. At this point, anti-B13, anti-1F8 and anti-JL7 titers were relatively close to the cut-off line, while anti-T. cruzi antibodies still remained positive. At baseline, 60.8% (45/74) of analysed patients tested positive for parasite DNA by PCR and during the follow-up period in 34 out of 45 positive samples (75.5%) could not be detected T. cruzi DNA. Our results suggest that these antigens might be useful as early markers for monitoring antiparasitic treatment in chronic Chagas disease. Instituto Oswaldo Cruz, Ministério da Saúde 2016-06 /pmc/articles/PMC4909034/ /pubmed/27223650 http://dx.doi.org/10.1590/0074-02760160006 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Niborski, Leticia L Grippo, Vanina Lafón, Sonia O Levitus, Gabriela García-Bournissen, Facundo Ramirez, Juan C Burgos, Juan M Bisio, Margarita Juiz, Natalia A Ayala, Vilma Coppede, María Herrera, Verónica López, Crescencia Contreras, Ana Gómez, Karina A Elean, Juan C Mujica, Hugo D Schijman, Alejandro G Levin, Mariano J Longhi, Silvia A |
| spellingShingle |
Niborski, Leticia L Grippo, Vanina Lafón, Sonia O Levitus, Gabriela García-Bournissen, Facundo Ramirez, Juan C Burgos, Juan M Bisio, Margarita Juiz, Natalia A Ayala, Vilma Coppede, María Herrera, Verónica López, Crescencia Contreras, Ana Gómez, Karina A Elean, Juan C Mujica, Hugo D Schijman, Alejandro G Levin, Mariano J Longhi, Silvia A Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina |
| author_facet |
Niborski, Leticia L Grippo, Vanina Lafón, Sonia O Levitus, Gabriela García-Bournissen, Facundo Ramirez, Juan C Burgos, Juan M Bisio, Margarita Juiz, Natalia A Ayala, Vilma Coppede, María Herrera, Verónica López, Crescencia Contreras, Ana Gómez, Karina A Elean, Juan C Mujica, Hugo D Schijman, Alejandro G Levin, Mariano J Longhi, Silvia A |
| author_sort |
Niborski, Leticia L |
| title |
Serological based monitoring of a cohort of patients with chronic Chagas
disease treated with benznidazole in a highly endemic area of northern
Argentina |
| title_short |
Serological based monitoring of a cohort of patients with chronic Chagas
disease treated with benznidazole in a highly endemic area of northern
Argentina |
| title_full |
Serological based monitoring of a cohort of patients with chronic Chagas
disease treated with benznidazole in a highly endemic area of northern
Argentina |
| title_fullStr |
Serological based monitoring of a cohort of patients with chronic Chagas
disease treated with benznidazole in a highly endemic area of northern
Argentina |
| title_full_unstemmed |
Serological based monitoring of a cohort of patients with chronic Chagas
disease treated with benznidazole in a highly endemic area of northern
Argentina |
| title_sort |
serological based monitoring of a cohort of patients with chronic chagas
disease treated with benznidazole in a highly endemic area of northern
argentina |
| description |
This study aimed to evaluate well-documented diagnostic antigens, named B13, 1F8 and
JL7 recombinant proteins, as potential markers of seroconversion in treated chagasic
patients. Prospective study, involving 203 patients treated with benznidazole, was
conducted from endemic areas of northern Argentina. Follow-up was possible in 107 out
of them and blood samples were taken for serology and PCR assays before and 2, 3, 6,
12, 24 and 36 months after treatment initiation. Reactivity against
Trypanosoma cruzi lysate and recombinant antigens was measured by
ELISA. The rate of decrease of antibody titers showed nonlinear kinetics with an
abrupt drop within the first three months after initiation of treatment for all
studied antigens, followed by a plateau displaying a low decay until the end of
follow-up. At this point, anti-B13, anti-1F8 and anti-JL7 titers were relatively
close to the cut-off line, while anti-T. cruzi antibodies still
remained positive. At baseline, 60.8% (45/74) of analysed patients tested positive
for parasite DNA by PCR and during the follow-up period in 34 out of 45 positive
samples (75.5%) could not be detected T. cruzi DNA. Our results
suggest that these antigens might be useful as early markers for monitoring
antiparasitic treatment in chronic Chagas disease. |
| publisher |
Instituto Oswaldo Cruz, Ministério da Saúde |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909034/ |
| _version_ |
1613595154932826112 |